Literature DB >> 25298324

[Artificial cornea: current treatment options and future perspectives].

C Cursiefen1.   

Abstract

Mesh:

Year:  2014        PMID: 25298324     DOI: 10.1007/s00347-013-3008-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


× No keyword cloud information.
  7 in total

1.  Pentacam-based big bubble deep anterior lamellar keratoplasty in patients with keratoconus.

Authors:  Stephan Riss; Ludwig M Heindl; Bjoern O Bachmann; Friedrich E Kruse; Claus Cursiefen
Journal:  Cornea       Date:  2012-06       Impact factor: 2.651

Review 2.  Expanding indications for the Boston keratoprosthesis.

Authors:  Kathryn A Colby; Euna B Koo
Journal:  Curr Opin Ophthalmol       Date:  2011-07       Impact factor: 3.761

3.  Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs.

Authors:  Yanyan Koenig; Felix Bock; Friedrich E Kruse; Katja Stock; Claus Cursiefen
Journal:  Cornea       Date:  2012-08       Impact factor: 2.651

Review 4.  Descemet stripping endothelial keratoplasty--rapid recovery of visual acuity.

Authors:  Philip Maier; Thomas Reinhard; Claus Cursiefen
Journal:  Dtsch Arztebl Int       Date:  2013-05-24       Impact factor: 5.594

Review 5.  Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases.

Authors:  Felix Bock; Kazuichi Maruyama; Birgit Regenfuss; Deniz Hos; Philipp Steven; Ludwig M Heindl; Claus Cursiefen
Journal:  Prog Retin Eye Res       Date:  2013-01-22       Impact factor: 21.198

Review 6.  [Human leukocyte antigen (HLA) system in ophthalmology].

Authors:  T Lapp; D Reinhold; D Böhringer; T Reinhard
Journal:  Ophthalmologe       Date:  2013-09       Impact factor: 1.059

Review 7.  Recent advances in the design of artificial corneas.

Authors:  May Griffith; Damien G Harkin
Journal:  Curr Opin Ophthalmol       Date:  2014-05       Impact factor: 3.761

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.